生物标志物发现
生物标志物
癌症生物标志物
DNA甲基化
医学
癌症
疾病
生物信息学
计算机科学
计算生物学
风险分析(工程)
生物
内科学
病理
蛋白质组学
基因
基因表达
生物化学
作者
Joe Ibrahim,Marc Peeters,Guy Van Camp,Ken Op de Beeck
标识
DOI:10.1016/j.ejca.2022.10.015
摘要
The increase in recent scientific studies on cancer biomarkers has brought great new insights into the field. Moreover, novel technological breakthroughs such as long read sequencing and microarrays have enabled high throughput profiling of many biomarkers, while advances in bioinformatic tools have made the possibility of developing highly reliable and accurate biomarkers a reality. These changes triggered renewed interest in biomarker research and provided tremendous opportunities for enhancing cancer management and improving early disease detection. DNA methylation alterations are known to accompany and contribute to carcinogenesis, making them promising biomarkers for cancer, namely due to their stability, frequency and accessibility in bodily fluids. The advent of newer minimally invasive experimental methods such as liquid biopsies provide the perfect setting for methylation-based biomarker development and application. Despite their huge potential, accurate and robust biomarkers for the conclusive diagnosis of most cancer types are still not routinely used, hence a strong need for sustained research in this field is still needed. This review provides a brief exposition of current methylation biomarkers for cancer diagnosis and early detection, including markers already in clinical use as well as various upcoming ones. It also outlines how recent big data and novel technologies will revolutionise the next generation of cancer tests in supplementing or replacing currently existing invasive techniques.
科研通智能强力驱动
Strongly Powered by AbleSci AI